TG Therapeutics Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? TG Therapeutics Inc trades at $54.06 (market cap $8.26B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $425.52 (market cap $1.88T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 227.6× TG Therapeutics Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.94% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TSM | |
|---|---|---|
Market Cap | $8.26B | $1.88T |
Sector | Health | Technology |
52-Week High | $59.06 | $477.57 |
52-Week Low | $26.39 | $227.33 |
Enterprise Value | $8.50B | $1.81T |
Dividend Yield | — | 0.94% |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →